Table 2.
Clinical studies of Melissa officinalis.
| Design | Observations | Country | Ref |
|---|---|---|---|
| Randomized, double-blind, placebo-controlled | In this study, the effect of M. officinalis supplementation was evaluated on borderline hyperlipidemia patients. The herbal capsule of M. officinalis extract showed significant results in hyperlipidemic patients. It reduced the level of low-density lipoprotein (LDL) and aspartate transaminase (AST) at the dose of 500 mg (two capsules of M. officinalis three times per day up to 2 months) (trial registration number: IRCT2014042017347N1). |
Iran | [138] |
| Randomized, crossover trial, placebo-controlled | In this study, investigations on safety, tolerability, and pharmacokinetics of a single dose of M. officinalis extract were performed. A single dose of M. officinalis extract containing 500 mg rosmarinic acid seems to be safe and tolerable in healthy individuals. It does not affect liver, kidney, and blood cell functions, and no harmful effects were reported during this study by the patients (trial registration number: UMIN000004997). |
Japan | [139] |
| Randomized, double-blind, placebo-controlled | In this study, the effect of M. officinalis extract was assessed against heart palpitation. Leaf extract of M. officinalis (500 mg two times per day up to 14 days) significantly reduced the incidence of palpitation and the number of anxious patients. It showed safe and beneficial effects in the treatment of palpitation patients, and no side effects were recorded during this study (trial registration number: IRCT2013012712303N1). |
Iran | [111] |
| Prospective pilot study, single-center, open-label | In this study, the effects of Cyracos (standardized extract of M. officinalis) were evaluated against anxiety disorders and sleep disturbance. Chronic administration of leaf extract of M. officinalis (600 mg per day up to 15 days) reduced the stress-related effects including anxiety manifestations (18%), ameliorated anxiety-associated symptoms (15%), and insomnia (42%). |
France | [140] |
| Randomized, double-blind, placebo-controlled | In this study, the effect of M. officinalis oil was estimated against agitation in Alzheimer's disease. Aromatherapy with Melissa oil was not effective compared to the known drug (trial registration number: EudraCT23148/0001/001-0001). |
UK | [141] |
| Randomized, double-blind, placebo-controlled | In this study, anxiolytic effects of the herbal combination were evaluated during the laboratory-induced stress. M. officinalis (80 mg) and Valeriana officinalis (120 mg) were used as a combination, and their 600 mg dose improved the negative effects of the defined intensity stressor simulation on ratings of anxiety. |
UK | [142] |
| Randomized, double-blind, placebo-controlled | In this study, the effectiveness and side effects of M. officinalis with two other herbs were evaluated against infantile colic. After the 1-week treatment of the herbs, crying time was reduced in 85.4% of subjects compared to control (48.9%) and no side effects were recorded during the study. |
Italy | [143] |
| Randomized, double-blind, placebo-controlled | In this study, the effects of M. officinalis on laboratory-induced psychological stress were investigated. The 600 mg dose of herbal extract reduced the negative mood effects of the defined intensity stressor simulation and increased the self-ratings of calmness. |
UK | [144] |
| Randomized, double-blind, placebo-controlled | In this study, the effects of M. officinalis on modulation of mood and cognitive performance were evaluated. The results indicated that doses of Melissa at or above can improve cognitive performance and the dose of 1600 mg showed the best results. |
UK | [145] |
| Randomized, double-blind, placebo-controlled | In this study, the efficacy and safety of M. officinalis extract were evaluated in mild to moderate Alzheimer's disease patients. After the 4-month treatment, herbal extract (60 drops per day) showed a significant outcome on cognitive function compared to control. |
Iran | [113] |
| Randomized, double-blind, placebo-controlled | In this study, the effects of M. officinalis were investigated against herpes simplex infections and the results suggested that the ingredient of the Melissa gave protection against herpes simplex infections and early-stage treatment revealed itself as most effective. | Germany | [146] |